Drug Safety Communications

This webpage was developed to provide the public with easy access to important drug safety information. The webpage contains the most recent Drug Safety Communications from FDA as well as links for Early Communications, Follow-Up Early Communications, Information for Healthcare Professional sheets, and Public Health Advisories issued prior to January 29th, 2010. You can also find drug specific information using the Index to Drug-Specific Information.

 

2010 Drug Safety Communications

• Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug (3/12/2010)
• Ongoing safety review of oral bisphosphonates and atypical subtrochanteric femur fractures (3/10/2010)
• Ongoing safety review of Invirase (saquinavir) and possible association with abnormal heart rhythms (2/23/2010)
• Ongoing review of Avandia (rosiglitazone) and cardiovascular safety (2/22/2010)
• New safety requirements for long-acting inhaled asthma medications called Long-Acting Beta-Agonists (LABAs) (2/18/2010)
• Product Confusion with Maalox Total Relief and Maalox Liquid Products (2/17/2010)
• Erythropoiesis-Stimulating Agents (ESAs): Procrit, Epogen and Aranesp (2/16/2010)
• Risk of Progressive Multifocal Leukoencephalopathy (PML)with the use of Tysabri (natalizumab) (2/5/2010)
• Serious liver disorder associated with the use of Videx/Videx EC (didanosine) (1/29/2010)